Enveric Biosciences reports new preclinical data supporting non-hallucinogenic profile of lead drug candidate EB-003

PUBT · 2d ago
Enveric Biosciences reports new preclinical data supporting non-hallucinogenic profile of lead drug candidate EB-003
  • Enveric Biosciences released new preclinical results supporting a non-hallucinogenic profile for lead candidate EB-003.
  • Findings were presented now, based on live-cell testing that compared EB-003 with hallucinogenic and non-hallucinogenic reference compounds.
  • Data aligned with recent published research linking specific receptor signaling patterns to hallucinogenic risk, placing EB-003 in a non-hallucinogenic range.
  • Results support plans to move EB-003 into a first-in-human Phase 1 trial, a key step toward clinical validation.
  • A non-hallucinogenic profile could simplify trial execution, improve blinding, reduce monitoring burdens, support an outpatient model, and expand commercial scalability.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enveric Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260805599685) on August 05, 2026, and is solely responsible for the information contained therein.